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Chronic ulcers are an important and costly medical issue, imposing considerable pain, 
reduced mobility and decreased quality of life. The common pathology in these 
chronic wounds is excessive proteolytic activity, resulting in degradation of key 
factors critical to the ulcer’s ability to heal. Matrix metalloproteinases (MMPs), a 
large family of zinc-dependent endopeptidases, have been shown to have increased 
activity in chronic wound fluid (CWF), with many authors suggesting that they need 
to be inhibited for the ulcer to heal. The studies we report here show that the 
excessive MMP activity in CWF can be inhibited with the bisphosphonate 
alendronate, in the form of a sodium salt, a functionalised analogue, and tethered to a 
poly(2-hydroxy methacrylate) (PHEMA) hydrogel. Furthermore, these functionalised-
alendronate hydrogels appear to be biocompatible as assessed in a three-dimensional 
ex vivo human skin equivalent model. Together, these results highlight the potential 
use of a tethered MMP inhibitor to inhibit protease activity in wound fluid. This 
approach may improve wound healing as it still allows MMPs to remain active in the 
upper cellular layers of the ulcer bed where they perform vital roles in wound healing; 
thus may offer an attractive new device-orientated wound therapy.
Abstract
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1. INTRODUCTION
Many current topical treatments for chronic ulcers have been designed to rectify the 
imbalance of growth-factors in the wound bed. One example is Regranex® from 
Johnson & Johnson, which delivers platelet-derived growth factor from a hydrogel 
dressing. While products like these introduce a positive flux of growth factors into the 
wound, they have been found to be only minimally effective [1]. Many authors have 
postulated that this is due to the excessively high levels of proteolytic activity, namely 
MMP activity, found in CWF [1-4]. In view of this, it has been suggested that the 
addition of a protease inhibitor prior to topical treatment of the wound may promote 
healing [3, 5-7]. There are a number of specific synthetic inhibitors of MMPs, namely 
tetracyclines and their chemically modified derivatives, e.g. doxycycline [6, 8, 9]; 
hydroxamic acids, e.g. GM6001 [10]; and bisphosphonates, e.g. clodronate [11]. The 
bisphosphonates are particularly appealing for use in chronic ulcers as they have been 
used clinically for a number of years to treat MMP-related disorders. Furthermore, 
they exhibit low toxicity and are therefore generally well-tolerated [12].
Bisphosphonates are small molecules, specifically referred to as geminal 
bisphosphonates when two C—P bonds are found on the same carbon atom [13]. 
Quite similar to endogenous pyrophosphates, bisphosphonates replace the O—P with 
a C—P, thereby allowing two additional functional groups [14], as well as creating a 
hydrolysis-resistant P—C—P bond [15]. In terms of MMP-inhibition, they are 
capable of binding to divalent metal ions, e.g. Zn2+, Ca2+ [16], through a three-
dimensional structure that allows the coordination of one oxygen from the phosphate 
group with the cation [14]. This affinity for divalent cations can be increased even 
further if one of the functional groups is either a hydroxyl (OH) or a primary amine 
(NH2), as this then facilitates the formation of a tridentate conformation with the 
cation [14]. In addition, the nitrogen atom in the side chain must be in a particular 
spatial arrangement, as well as being a critical distance from the cation, for the 
bisphosphonate to be the most potent [17]. As a result, there has been a lot of work 
aimed at designing new and improved bisphosphonates in recent years, resulting in 
hundreds of new bisphosphonates being synthesised [17].
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Bisphosphonates have been shown to inhibit MMP-1, -2, -3, -8, -9, -12, -13 and -20 at 
both therapeutically obtainable and, most importantly, non-cytotoxic concentrations 
[16]. Current clinical applications generally include the management of calcium and 
bone metabolism disorders, e.g. osteoporosis, Paget’s disease, hypercalcaemia and 
metastatic cancer [15]. For a number of years now, these diseases have been 
effectively treated with bisphosphonates. Therefore, it appears that for future 
indications, including those primarily caused by significant soft tissue destruction, e.g. 
chronic ulcers, bisphosphonates may be a promising treatment [12]. In terms of 
chronic ulcer treatments, the delivery of specific bisphosphonates, or indeed simply 
the presentation of this particular chemical to the site of excessive protease activity, 
has to be carefully contemplated. This is due to more recent reports suggesting that 
the MMPs present in the ulcer environment may also be involved in other biological 
processes important to wound healing, such as growth factor activation and immune 
system regulation, rather than simply degrading the wound bed matrix and growth 
factors [18-21]. The goal of this study, which is significantly different from protease-
inhibitory strategies proposed by others, is therefore to inactivate the proteases in the 
wound fluid after the fluid is absorbed away from the actual wound bed. In this 
situation the proteases required for healing-associated functions within the upper 
cellular layers of the wound bed remain available.
Bisphosphonates have previously been modified for clinical delivery, especially in 
terms of bone-specific applications [22-24]. In addition, alendronate is a prime 
candidate bisphosphonate for functionalisation as it contains a primary amine – a 
convenient chemical group that can be easily manipulated for conjugation into a 
polymer using already-established methods [24]. Through a nucleophilic acyl 
substitution reaction, an amine, present in the alendronate sodium salt form, can be 
reacted with a vinyl-containing acid halide [25] to produce an alendronate tethered to 
an unsaturated carbon group. This group then allows for further polymerisation into 
an established hydrogel system. The experiments reported herein focus on the details 
surrounding this preliminary alendronate condensation reaction, and then describe 
how this alendronate-methacrylate can be copolymerised into a PHEMA/PEG 
hydrogel system. Furthermore, this bioactive wound dressing is tested for efficacy 
against protease activity in CWF, and is assessed in further cell-based assays to 
confirm biocompatibility with a human ex vivo skin model.
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2. MATERIALS AND METHODS
2.1 Chemicals
2-Hydroxyethyl methacrylate (HEMA, ≥ 99% GC, Sigma-Aldrich, St Louis, MO, 
USA) and methacryloyl chloride (Sigma-Aldrich) were distilled under reduced 
pressure immediately prior to use. Polyethylene glycol 20,000 (PEG, Sigma-Aldrich), 
peroxidase from horseradish (Sigma-Aldrich) and 2,2'-Azinobis [3-
ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS, Pierce 
Biotechnology, Rockford, IL, USA), alendronate sodium salt (Merck, San Diego, CA, 
USA) and 4-methoxy phenol (Sigma-Aldrich) were used as supplied under the 
manufacturers’ instructions. All H2O used was double deionised by ion exchange 
(MilliQ, Millipore, Billerica, MA, USA).
2.2 Functionalisation of alendronate 
In a round-bottom flask, alendronate sodium salt (300 mg, 0.92 mmol) was dissolved 
in aqueous NaOH (148 mg, 3.70 mmol in 7.4 mL H2O) with 4-methoxy phenol to 
inhibit polymerisation. The solution was cooled in an ice-salt bath then freshly 
distilled methacryloyl chloride (120 mg, 1.15 mmol) and NaOH (111 mg, 2.768 mmol 
in 5.5 mL H2O) was added step-wise, maintaining the pH above 11. The reaction was 
stirred vigorously for 20 hours, then acidified with HCl to pH 7. The resulting product 
was evaporated to dryness using a rotary evaporator and extracted with chloroform 
(CHCl3) to remove any impurities. The water layer was then precipitated with N,N-
dimethylformamide (DMF) to obtain alendronate-methacrylate.
2.3 Characterisation of alendronate-methacrylate through FT-NMR 
spectroscopy
31P spectra were recorded using a 400 MHz NMR Spectrometer (Bruker, Germany) at 
room temperature in deuterated water (D2O). Spectra were analysed using MestReC 
Version 4.9.9.6 software (Mestrelab Research, Santiago de Compostela, Spain).
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2.4 Wound fluid sample collection and preparation
Chronic wound fluid (CWF) samples were obtained from consenting patients of the 
St. Luke’s Nursing Services (Brisbane, QLD, Australia), suffering from chronic 
venous ulcers and undergoing compression therapy. Ethical approval to collect these 
samples was obtained from both the Queensland University of Technology (QUT) 
and St. Luke’s Nursing Services. A standard wound fluid collection technique has 
been established and was carried out at the clinical site. Briefly, ulcers were washed 
with sterile water prior to collecting wound fluid, followed by the application of an 
occlusive dressing over the wound. Exudate accumulated under the dressing after 30 
min to 1 h was recovered by washing with 1 mL of saline. The fluid was removed 
with 26G x 0.5” needle and syringes (Terumo Medical, Somerset, NJ, USA) and 
collected in 1.5 mL Protein LoBind tubes (Eppendorf, Hamburg, Germany). The 
wound fluid samples were centrifuged at 14,000 g for 10 min, then the supernatant 
was filtered using 0.45 µm cellulose acetate filters (Agilent Technologies, 
Wilmington, DE, USA). The protein content for all samples was quantitated and 
standardised using the BCA Protein assay kit (Pierce Biotechnology, Rockford, IL, 
USA). The samples were then sub-aliquoted and stored at -80 ºC until further 
analysis.
2.5 Analysis of MMP-inhibition through incubation with the alendronate-
methacrylate
A pooled sample of CWF was run on Collagen Type I zymograms as previously 
described [26] using Collagen Type I (Sigma-Aldrich) at a final concentration of 0.5 
mg/mL in 10% total acrylamide gels under non-reducing conditions. Briefly, 
electrophoresis was performed at 4 ºC under Laemmli conditions [27]. The gels were 
then washed in 2.5% Triton X-100 for 30 minutes, then a further 60 minutes, prior to 
incubation in 50 mM Tris-HCl, 10 mM CaCl2 and 50 mM NaCl at pH 7.6 for 24 
hours at 37 ºC, with the following exception. Alendronate-methacrylate (2 mM of the 
equivalent bisphosphonate segment of alendronate-methacrylate) and alendronate 
sodium salt (2 mM) were included in separate zymogram incubation buffers and the 
zymograms were incubated at 37 ºC for 24 hours. The gels were then stained using 
0.25% Coomassie brilliant blue R-250 (Bio-rad Laboratories, Hercules, CA, USA) 
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(40% methanol, 10% acetic acid) and destained appropriately (40% methanol, 10% 
acetic acid). Protease activity was visualised as clear (unstained) bands. 
2.6 Analysis and quantitation of collagen zymography
Gels were scanned using GeneSnap version 6.07 (SynGene, Cambridge, UK) and 
analysed using GeneTools version 3.07 to determine the molecular weight and 
quantitate the clear bands (SynGene). All quantitative analyses were performed using 
three separate gels per treatment and values were expressed as a relative % of the 
untreated sample, similar to previously published reports [28, 29]. 
2.7 Synthesis of hydrogels 
Aqueous solutions of distilled HEMA were prepared (50% water, 30% PEG and 20% 
HEMA) with a vehicle control without alendronate-methacrylate and two 
concentrations of alendronate-methacrylate (2 mM and 20 mM of the equivalent 
bisphosphonate segment of alendronate-methacrylate in the monomer solution) (Table 
1). Solutions were then placed between two glass plates separated by a silicone gasket 
and purged with argon. Each mould was approximately 75 mm x 50 mm x 3 mm and 
filled with 10 mL of monomer solution. The moulds were then exposed to gamma-
irradiation in a Gamma-cell 220 (Atomic Energy of Canada Ltd, Ottawa, Canada)
using a Co60 source at a rate of 3.25 kGy/h to give a total dose of 10 kGy (Table 4.1). 
The hydrogels were removed from their moulds and cut into 1 cm x 1 cm square 
pieces for further analysis.
2.8 Analysis of polymerisation through NIR FT-Raman Spectroscopy
Non-irradiated and irradiated samples were analysed by a Perkin Elmer System 2000 
NIR FT-Raman spectrophotometer (Perkin Elmer, Waltham, MA, USA). The 
hydrogel samples were placed into glass vials for spectroscopic analysis and the 
spectra were analysed using Grams/AI (Thermo Electron Corporation, Waltham, MA, 
USA).
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2.9 Analysis of MMP-inhibition through incubation with the alendronate-
functionalised hydrogels
Similar to that described above, a pooled sample of CWF was analysed through 
Collagen Type I zymography with the following alteration. Alendronate-
functionalised hydrogels were cut into small pieces and included in the incubation 
buffer, along with a blank and a non-functionalised hydrogel to act as a vehicle 
control, and then incubated at 37 ºC for 24 hours. Collagen Type I zymograms were 
then analysed as described previously.
2.10 Skin collection
Skin samples were collected from consenting patients undergoing breast or abdomen 
reductions at the St. Andrews and Wesley Hospitals, Brisbane, QLD, Australia. 
Human ethical approval was obtained from both the hospitals and the Queensland 
University of Technology. The skin samples were collected in sterile jars containing 
antibiotic/antimycotic solution containing 10,000 units of penicillin/mL, 10,000 µg of 
streptomycin/mL and 25 µg of amphotericin B/mL, with penicillin G, streptomycin 
sulfate and amphotericin B as antimycotic in 0.85% saline (Invitrogen, Carlsbad, CA, 
USA). These samples were processed within 12 hours following storage at 4 ºC in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing antibiotics.
2.11 Primary keratinocyte cell cultures
Primary skin keratinocytes were isolated as previously described [30] and expanded 
on a feeder layer of lethally irradiated 3T3 mouse fibroblast feeder cells (i3T3s) in 
Green’s Media [31] that contained 10% foetal calf serum (FCS – Hyclone, Logan, 
UT, USA). Keratinocytes were grown for 7 days with the medium replaced every 3-4 
days.
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2.12 Preparation of a three-dimensional human skin epidermis equivalent
model 
A human skin equivalent (HSE) model was used as previously described [30] with the 
following modifications. Following keratinocyte addition to the sterile stainless steel 
rings on top of the HSEs, the composites were incubated for 24 hours at 37 ºC/5% 
CO2. After this period, the rings were removed and the composites were raised to the 
air-liquid interface by moving them onto stainless steel grids in 6-well plates (Nunc). 
The cultures were maintained for 5 days at 37 ºC/5% CO2 before the hydrogel 
treatments were applied.
2.13 Biocompatibility testing of hydrogels using the HSE model
At five days post air-liquid interface culture, the alendronate-functionalised hydrogels 
were placed on top of the composite, along with “no treatment” and “non-
functionalised” hydrogels as controls. These hydrogels were exposed to the composite 
for 7 days at 37 ºC/5% CO2, with the media being replaced at 3 days. At completion 
of the treatment, samples of the composite model were fixed and paraffin-embedded 
using standard protocols for haematoxylin and eosin (H&E) histological analysis. 
2.14 Immunohistochemistry
Paraffin sections of the HSEs were cut (3 μm sections) and then deparaffinised in 
ethanol and xylene. Briefly, this involved sequential incubations with solutions of 
100% xylene, 100% ethanol, 95% ethanol, 70% ethanol and distilled water. Sections 
were then probed separately for: keratin 1/10/11 (K1/10/11), a marker for 
cornification and squamous cell differentiation; p63 (RDI Research Diagnostics, 
Concord, MA, USA), a p53 analogue that identifies normal basal cells as opposed to 
malignant tumours; and cleaved caspase-3 (Cell Signaling Technology, Danvers, MA, 
USA), a critical mediator of apoptosis in mammalian cells. For slides that were 
probed for cleaved caspase-3, antigen unmasking was required before the blocking 
step. Briefly, the slides were incubated at 37 ºC in 10 mM citrate buffer (pH 3.0) for 
30 min, before proceeding as normal. After incubation with primary antibodies for 
K1/10/11 (1:400), p63 (1:100) and cleaved caspase-3 (1:100), the sections were 
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probed using a Dako Envision kit (Dako Denmark A/S, Glostrup, Denmark) as per the 
manufacturer’s instructions, with the exception that phosphate buffered saline (PBS) 
was used instead of TBS. After antibody development of the labelled secondary 
antibody with the 3,3’ diaminobenzidine (DAB) chromogen solution, all sections 
were counterstained with haematoxylin for 30 seconds and analysed using light 
microscopy.
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3. RESULTS
3.1 Synthesis and characterisation of alendronate-methacrylate
Following the identification of excessive MMP-9 levels in CWF as described in 
previous studies [32, 33], potential MMP inhibitors were considered for incorporation 
into a hydrogel wound dressing. The bisphosphonate alendronate was chosen as it has 
been used for a number of years in clinical practice [15] and possessed an easily 
modified primary amine. The primary amine in alendronate was reacted with 
methacryloyl chloride to form the amide along with a pendant vinyl group (Figure 
1A). This unsaturated carbon then allowed for further polymerisation (Figure 1B) into 
an aqueous PHEMA:PEG hydrogel system. The 31P spectra of the methacrylated 
product, along with the original alendronate, are shown in Figure 2. All peaks have 
been assigned and further details of the spectrum are outlined in Table 2. In Figure 2C
a second triplet is seen upfield of the first, which can be assigned to a dimer of the
original alendronate-methacrylate formed through P—O—P bonds of the 
bisphosphonate groups (Figure 3), and not the starting product as shown by the shift 
upfield. 
3.2 Analysis of MMP-inhibitory action of alendronate-methacrylate
To analyse the alendronate-methacrylate, an activity assay was used to compare its 
MMP-inhibitory activity to that of the original alendronate. Through incubation of 
CWF with increasing concentrations of either the original or the alendronate-
methacrylate, the proteolytic activity was revealed by the use of Collagen Type I
(Figure 4A-B). This demonstrated that both forms of the alendronate are able to 
inhibit CWF samples 1-6 to varying degrees. Densitometry was used to quantify the 
reduction in proteolytic activity revealed by zymography and are represented 
graphically in Figure 4C. Quantitatively, both inhibitors were able to decrease the 
amount of Collagen Type I degradation, as compared to the untreated CWF samples 
(p<0.01). From this functional assay, it appears that the addition of the methacrylate 
group to alendronate still allows for inhibition of MMPs at a physiological 
temperature over 24 hours, although at a reduced level of function compared to the 
native form. 
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3.3 Preparation and characterisation of alendronate-functionalised hydrogels
Following successful inhibition of MMPs in CWF with the alendronate-methacrylate, 
polymerisation was required to form the functionalised wound dressing. Three sets of 
hydrogels were successfully synthesised according to the conditions outlined earlier 
(Table 1, Figure 1B). NIR FT-Raman Spectroscopy demonstrated that a total dose of 
10 kGy of gamma irradiation induced complete polymerisation of the alendronate-
methacrylate and HEMA monomer to its copolymer form (Figure 5). This was 
evident by the absence of a characteristic C=C band at 1639 cm-1 in the irradiated 
samples when compared with the monomer mixture. The hydrogel sheets were then 
characterised using both a functional protease assay, along with exposure to a three-
dimensional ex vivo skin model to determine biocompatibility.
3.4 Analysis of MMP-inhibitory action of alendronate-functionalised 
hydrogels
The alendronate-functionalised hydrogels were analysed using Type I Collagen 
zymography to determine if the tethered alendronate still demonstrated MMP-
inhibitory action. The hydrogels were cut into small pieces and incubated with the 
zymograms containing the CWF, along with an untreated control. Collagen Type I 
zymography of the pooled CWF samples showed a large amount of protease activity 
in the untreated control (lane 1) (Figure 6A). However, when the hydrogel pieces 
were present, all three treatments showed a visible decrease in the amount of Collagen 
Type I degradation (lanes 2-4) (Figure 6A). When the treatments were analysed using 
densitometry to quantitate the relative decrease in protease activity, the GA10X 
hydrogel, i.e. the hydrogel containing 20 mM of alendronate-methacrylate, displayed 
the ability to significantly reduce Collagen Type I degradation as compared with the 
non-hydrogel treated control (p<0.01) (Figure 6B). These results suggest the tethered 
alendronate is still able to inhibit MMPs as shown through a functional assay.   
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3.5 Biocompatibility testing using a three-dimensional human skin equivalent
A three-dimensional human epidermal skin equivalent model was used to assess
potential toxicity effects from the alendronate-functionalised hydrogels as compared 
to the vehicle hydrogel. The various hydrogels were applied to the stratified skin 
models for a seven-day period, with histological and immunochemical staining 
carried out upon completion of the experiment. Treatments included the vehicle 
control of hydrogel G, along with the two alendronate-functionalised hydrogels, 
GA1X and GA10X. Histological analysis showed a haematoxylin-stained basal layer, 
with an eosin-stained cornified layer of relatively the same thickness throughout for 
all treatments (Figure 7). For the GA10X hydrogel minimal basal cells are apparent, 
along with increased numbers of nucleated cells in the cornified layer. Hydrogel G 
and GA1X also show some nucleated cells in the cornified layer, however, they do 
not appear to be as numerous. When the sections were probed for specific skin 
markers, keratin 1/10/11 and p63, and the apoptotic marker, cleaved caspase-3,
hydrogel GA10X revealed a minimal amount of p63 immunoreactive basal cells, 
confirming the histological analysis. In the control and hydrogel G treatments, there is 
no visible immunoreactivity of cleaved caspase-3 with apoptotic cells. Similarly,
minimal cleaved caspase-3 immunoreactivity is evident in samples exposed to its 
functionalised counterparts, GA1X and GA10X. This indicates that the synthesised 
hydrogels appear promising for potential wound dressing treatments.
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4. DISCUSSION
MMP-9 has been previously identified as an abundant protease present in CWF, and
is likely to have a key role in degrading both the extracellular matrix and growth 
factors in the chronic wound environment. Hence, it is not surprising that current 
topical treatments of chronic ulcers with bioactives, i.e. growth factors, have proven 
to be only slightly effective in treating this condition [1]. In view of this, a specific 
MMP inhibitor, namely the bisphosphonate alendronate, was chosen as a potential 
clinical treatment to aid in neutralising the aggressive proteolytic chronic wound 
environment; the ultimate goal of this strategy being to modulate the ulcer towards a 
healing state. The bisphosphonate family, which exhibits low toxicity and has been 
well tolerated for several years of human use, seems to be the ideal candidate for 
MMP-related diseases [12]. The wound treatment explored in this study examined the 
use of bisphosphonates to inhibit MMP activity in CWF. Importantly, the approach 
described differs significantly from previous methods in that we proposed inactivation 
of the proteases in the wound fluid, after the fluid is absorbed away from the actual 
wound bed, so that proteases required for wound healing-related functions within the 
upper cellular layers of the wound bed remain available. 
Alendronate was chosen as the MMP-inhibitor for inclusion into the hydrogel, 
primarily due to the fact that it contains both amine and hydroxyl functional groups, 
which together can enhance the bisphosphonate’s affinity for divalent cations [14].
However, it first has to be modified to allow further polymerisation into the synthetic 
wound dressing. Because alendronate is insoluble in common organic solvents, a two 
phase Shotten-Baumann reaction was chosen to react an acid chloride with the amine 
of alendronate. This reaction is well characterised and allows high yields of amides, 
mainly due to the fact that they are able to successfully compete with other reactive 
species present [34]. Briefly, this is a two phase reaction with the acid chloride 
suspended in the water phase containing the amine compound. At the boundary of the 
two phases, the amine reacts with the acid chloride, thereby generating the desired 
product. The 31P spectra showed an additional phosphorus-containing species in the 
resulting product, possibly due to the dimerisation of two functionalised alendronate 
molecules through the –OH group on the phosphate. Similar dimerisation has been 
shown with a similar phosphate-containing molecule, i.e. ethylene glycol 
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methacrylate phosphate (MOEP) [35]. Following the reaction to modify alendronate, 
the resulting product was then copolymerised into a PHEMA hydrogel system. FT-
Raman spectroscopy revealed a complete polymerisation, thereby ensuring that no 
functionalised alendronate could be released from the hydrogel.
Critically, we demonstrate that alendronate tethered to a hydrogel was able to 
significantly decrease the levels of Type I Collagen degradation in CWF as compared 
to the untreated control (p<0.01). Interestingly, the vehicle hydrogel, i.e. the hydrogel 
without the alendronate-methacrylate, was also able to inhibit MMP activity as 
revealed through the Collagen Type I zymography, but to a lesser degree than the 
most concentrated alendronate-functionalised hydrogel, GA10X. A possible 
explanation for this is the chemical composition of PHEMA itself, as it contains three
oxygen atoms in its unit structure that are all available for chelation [36]. Further 
evidence for this hypothesis is that Ca2+ itself has a strong tendency to chelate to 
oxygen atoms [37]. Therefore, through the use of a “self-chelating” hydrogel support, 
the vehicle treatment (hydrogel G) has the ability to chelate the cations required by 
MMPs for their stability and catalytic activity, e.g. Ca2+, Zn2+. This chelating ability is 
then disrupted by copolymerisation with the alendronate-methacrylate at the lowest 
concentration (hydrogel GA1X). Zainuddin et al. (2006) previously postulated that by 
reducing the number of available oxygen atoms, the chelating mechanism is thereby 
reduced, and may then prevent the chelation of metal ions with PHEMA. 
Furthermore, Chirila et al. (2007) report massive calcification of PHEMA, both in 
vitro in simulated body fluid and in vivo as subcutaneous implants [38]. However, 
when the highest concentration of alendronate-methacrylate is copolymerised into the 
system (GA10X), the chelating ability of alendronate alone is stronger than the 
PHEMA support and overcomes the decreased response seen with GA1X. Therefore, 
taken together, these results indicate that the alendronate is still available to inhibit the 
MMPs in the CWF, while not being released into the wound bed. This is a significant 
advance over topically applied inhibitors as it allows MMPs to remain active in the 
wound bed where they perform vital roles in growth factor activation and immune 
system regulation [18-21], yet at the same time the unwanted MMPs, those in the 
CWF, are absorbed into the hydrogel where they are inactivated.
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Three-dimensional ex vivo skin models are a useful tool for evaluating topical
products, as well as overcome a number of ethical and practical issues associated with 
animal studies [39]. Furthermore, 3D-stratified layers of human epidermal cells grown 
in culture systems in vitro have been shown to be useful in assessing skin irritation 
potential [40]. Following on from this, the experiments reported herein showed that 
there were minimal differences between the three treatments, i.e. the vehicle and two 
alendronate-functionalised hydrogels, in terms of impact on visible structure and 
effect on a range of skin cell surface expression markers on the HSE model. An 
interesting point to note is that with both wound dressing treatments, nucleated cells 
became visible in the previously anuclear cornified layer. We suspect that the 
application of a topical dressing to the skin equivalent model results in culture 
medium being absorbed into the dressing, and therefore converts the air-liquid 
interface of the 3D skin model to a liquid-liquid interface. This may then stimulate the 
keratinocytes to migrate faster through the cornified layers and produce a more 
immature phenotype. This particular behaviour has also been described in previous 
reports, where cells in a similar three-dimensional skin model did not completely 
differentiate when still covered with culture medium [41]. Indeed, this may well 
underlie the well accepted evidence that a moist wound environment is essential for 
optimal wound healing [42]. 
In terms of expression of skin cell surface markers, the HSEs exposed to the three 
hydrogel treatments appeared to be relatively similar when probed with the skin 
differentiation marker keratins 1, 10 and 11 and the basal cell marker, p63. The main 
difference observed between the HSEs exposed to the three treatments was that
minimal immunoreactivity was observed with p63 in the GA10X hydrogel. This is 
likely to be alleviated by first washing the alendronate-functionalised hydrogels –
thereby minimising the increased adhesive potential, or “stickiness”, of the 
phosphonate polymer component, such as that demonstrated in previous adhesion 
studies using human peripheral blood mononuclear cells [43]. Apoptosis in the 
keratinocytes in the HSE was also analysed by immunoprobing for cleaved caspase-3 
– a major effector caspase that is specific for keratinocytes undergoing apoptosis and 
not just those undergoing terminal differentiation [44]. None of the three treatments 
showed large levels of immunoreactivity to this cell surface marker, which appears 
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promising for future clinical treatments, especially in terms of developing MMP-
inhibiting, CWF-absorbing functionalised hydrogels.
16.
5. CONCLUSION
Taken together, the results reported herein suggest this novel alendronate-
functionalised hydrogel holds promise as a dressing treatment for chronic wounds. 
This is due to its ability to inhibit the excessive levels of MMPs in CWF, as well as its 
biocompatibility when exposed to a human ex vivo skin model. Of importance to the 
development of this wound dressing was the ability to attach a functional group to the 
alendronate sodium salt, which then allowed polymerisation into the hydrogel system. 
This was achieved through a Shotten-Baumann reaction of the primary amine of 
alendronate with methacryloyl chloride, which permitted high yields of the amide in a 
single-step reaction. Furthermore, we have demonstrated that the MMPs in CWF can 
be inhibited by the original bisphosphonate alendronate, the methacrylated-analogue, 
and in a tethered state, i.e. attached to a hydrogel support. This last point is critical to 
the development of a successful chronic ulcer wound dressing as it inhibits the MMPs 
in CWF, while still allowing those on the wound bed itself to perform their essential 
functions in wound healing, namely, activation of growth-promoting agents and 
immune system modulation.
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Figure 1. Reaction schemes. 
(A) Condensation reaction of methacryloyl chloride and alendronate sodium salt. 
(B) Gamma-induced polymerisation of HEMA and alendronate-methacrylate.
Figure 2. FT-NMR 31P spectrum of alendronate-methacrylate. 
(A) Labelled schematic of alendronate-methacrylate. 
(B) 31P spectrum of alendronate. 
(C) 31P spectrum of alendronate-methacrylate.
Figure 3. Potential structure of alendronate-methacrylate dimer.
Figure 4. Collagen Type I zymography demonstrating inhibition of protease 
activity present in wound fluid samples by alendronate sodium salt and its 
methacrylated-counterpart.
(A) Lanes 1-6 are CWF samples 1-6 (500 ng); Lanes 7-12 are CWF samples 1-6 
(500 ng) with 2 mM of alendronate (A) present in the incubation buffer at 37 ºC for 24 
hours.
(B) Lanes 1-6 are CWF samples 1-6 (500 ng); Lanes 7-12 are CWF samples 1-6 
(500 ng) with 2 mM of alendronate-methacrylate (functionalised A) present in the 
incubation buffer at 37 ºC for 24 hours.
(C) Relative levels of protease activity in pooled CWF samples treated with 
respective inhibitors. The MMP-specific inhibition of collagen degrading activity was 
represented quantitatively through densitometric analysis. Levels are shown as the % 
collagen degrading activity as compared to the untreated samples, ± SEM (n=3). 
Statistical significance is relative to the untreated samples and shown as # (p<0.01) as 
determined by Tukey’s test.
Figure 5. Analysis of alendronate-functionalised hydrogels using NIR FT-
Raman Spectroscopy. Spectra indicate intensity/ Raman shift in cm-1.
(A) Unirradiated H2O:HEMA:PEG
(B) GA1X
Irradiated H2O:HEMA:PEG:1X alendronate-methacrylate (10 kGy)
(C) GA10X
Irradiated H2O:HEMA:PEG:10X alendronate-methacrylate (10 kGy)
Captions
Figure 6. Collagen Type I zymography demonstrating inhibition of protease 
activity present in wound fluid samples by alendronate-functionalised hydrogels.
(A) Lane 1 is the pooled CWF sample with no treatment in the incubation buffer. 
Lanes 2-4 are the same pooled CWF sample with polymer G, GA1X and GA10X 
(Table 1) respectively cut into small pieces and present in the incubation buffer at    
37 ºC for 24 hours.
(B) Relative levels of protease activity in pooled CWF samples treated with the 
respective hydrogels. The MMP-specific inhibition of collagen degrading activity was 
represented quantitatively through densitometric analysis. Levels are shown as the % 
collagen degrading activity as compared to the control sample, ± SEM (n=3). 
Statistical significance is relative to the control sample and shown as # (p<0.01) as 
determined by Tukey’s test.
Figure 7. Histological and immunohistochemical analysis of an ex vivo
human skin model following exposure to the alendronate-functionalised
hydrogel. From left to right the staining is: haematoxylin and eosin (H&E), keratin 
1/10/11 (K1/10/11), p63 and cleaved caspase-3 (CC-3). The scale bar measures 20 
µm. Hydrogel treatments are defined in Table 1.
1.
Sample ID H2O (g) HEMA (g) PEG 20,000 (g)
Alendronate-
methacrylate (mg)
G 5.0 2.0 3.0 -
GA1X 5.0 2.0 3.0 7.68
GA10X 5.0 2.0 3.0 76.80
Table 1. Functionalised hydrogel formulations prepared for analysis as 
potential wound dressings
Peak ppm
Multiplicity, 
coupling constant 
(Hz)
Norm. 
Int
Identity
21.51
21.43a,b
21.35
t, 12.7 1.00
P on alendronate-
methacrylate, split by CH2
21.16
21.091
21.01
t, 11.8 0.35
P on alendronate-
methacrylate dimer (Figure 
3), split by CH2
Table 2. Features of alendronate-methacrylate FT-NMR 31P spectrum. 
Columns are from left to right: peak number; shift (ppm); multiplicity (s, d, t, m) and 
coupling constant (Hz); normalised integral; and identity.
Table
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